PilVax – a novel peptide delivery platform for the development of mucosal vaccines
Open Access
- 7 February 2018
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-12
Abstract
Peptide vaccines are an attractive strategy to engineer the induction of highly targeted immune responses and avoid potentially allergenic and/or reactogenic protein regions. However, peptides by themselves are often unstable and poorly immunogenic, necessitating the need for an adjuvant and a specialised delivery system. We have developed a novel peptide delivery platform (PilVax) that allows the presentation of a stabilised and highly amplified peptide as part of the group A streptococcus serotype M1 pilus structure (PilM1) on the surface of the non-pathogenic bacterium Lactococcus lactis. To show proof of concept, we have successfully inserted the model peptide Ova324–339 into 3 different loop regions of the backbone protein Spy0128, which resulted in the assembly of the pilus containing large numbers of peptide on the surface of L. lactis. Intranasal immunisation of mice with L. lactis PilM1-Ova generated measurable Ova-specific systemic and mucosal responses (IgA and IgG). Furthermore, we show that multiple peptides can be inserted into the PilVax platform and that peptides can also be incorporated into structurally similar, but antigenically different pilus structures. PilVax may be useful as a cost-effective platform for the development of peptide vaccines against a variety of important human pathogens.Keywords
This publication has 54 references indexed in Scilit:
- Controlled Inflammatory Responses in the Lungs Are Associated with Protection Elicited by a Pneumococcal Surface Protein A-Based Vaccine against a Lethal Respiratory Challenge with Streptococcus pneumoniae in MiceClinical and Vaccine Immunology, 2012
- Defining and searching for structural motifs using DeepView/Swiss-PdbViewerBMC Bioinformatics, 2012
- The ancillary protein 1 of Streptococcus pyogenes FCT‐1 pili mediates cell adhesion and biofilm formation through heterophilic as well as homophilic interactionsMolecular Microbiology, 2012
- Lactococcus lactis-based vaccines from laboratory bench to human use: An overviewVaccine, 2012
- Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccinesMicrobial Cell Factories, 2011
- Crystal Structure of the Minor Pilin FctB Reveals Determinants of Group A Streptococcal Pilus AnchoringJournal of Biological Chemistry, 2010
- Cell Surface of Lactococcus lactis Is Covered by a Protective Polysaccharide PellicleJournal of Biological Chemistry, 2010
- A Foreign Protein Incorporated on the Tip of T3 Pili in Lactococcus lactis Elicits Systemic and Mucosal ImmunityInfection and Immunity, 2010
- The SWISS-MODEL workspace: a web-based environment for protein structure homology modellingBioinformatics, 2005
- Antigenic and allergenic determinants of ovalbumin—III. MHC Ia-binding peptide (OA 323–339) interacts with human and rabbit specific antibodiesMolecular Immunology, 1990